Oculis to Showcase Pipeline at Piper Sandler Ophthalmology Conference
Event summary
- Oculis to present at Piper Sandler Virtual Ophthalmology Conference on July 10, 2026.
- CFO Sylvia Cheung will lead a fireside chat discussing the company's late-stage pipeline.
- Key highlights include Privosegtor for optic neuritis and Licaminlimab for dry eye disease.
- Privosegtor has received Breakthrough Therapy designation from FDA and PRIME designation from EMA.
- Company targets an estimated $7B+ market opportunity in the U.S. alone.
The big picture
Oculis' participation in the Piper Sandler conference underscores its push to position itself as a leader in neuro-ophthalmic treatments. The company's focus on regulatory designations for Privosegtor highlights its strategy to differentiate through accelerated approval pathways, while Licaminlimab represents a novel approach to dry eye disease. The $7B+ market opportunity signals significant potential if the pipeline delivers.
What we're watching
- Regulatory Momentum
- Whether Privosegtor's Breakthrough Therapy and PRIME designations will accelerate approval timelines.
- Market Penetration
- The pace at which Oculis can capture the $7B+ U.S. market for optic neuritis treatments.
- Pipeline Execution
- How Oculis will balance development of Privosegtor and Licaminlimab amid competing priorities.